# Myeloid HDAC3 deletion protects against traumatic optic injury

**Authors:** Rami A. Shahror, Carol A. Morris, Ashlynn Cunningham, Piyanan Chuesiang, Abdelrahman Y. Fouda

PMC · DOI: 10.1038/s41420-026-03030-0 · Cell Death Discovery · 2026-03-18

## TL;DR

Deleting HDAC3 in myeloid cells protects against optic nerve injury and improves recovery after trauma.

## Contribution

Myeloid HDAC3 deletion, not microglial deletion, enhances efferocytosis and protects retinal ganglion cells after optic nerve injury.

## Key findings

- Myeloid HDAC3 deletion preserves retinal ganglion cells and improves axonal regeneration after optic nerve crush.
- HDAC3 deletion enhances macrophage phagocytosis of apoptotic cells and myelin debris.
- The protective effects are linked to increased MerTK expression in macrophages.

## Abstract

Traumatic optic neuropathy (TON) occurs due to trauma to the optic nerve, resulting in blindness. Current management focuses primarily on supportive care, highlighting an urgent need to identify novel treatment targets. Neuronal expression of the enzyme histone deacetylase 3 (HDAC3) has been previously implicated in retinal ganglion cell (RGC) degeneration after optic nerve crush (ONC), a model of TON. Here we investigated the role of myeloid HDAC3 (i.e., HDAC3 expressed in microglia and macrophages) in RGC loss, axonal degeneration, and efferocytosis, a reparative process by which phagocytic myeloid cells engulf apoptotic cells. ONC injury was performed on myeloid-specific HDAC3 knockout (KO) and floxed control mice. Neurodegeneration and efferocytosis assays were assessed using retina flatmount immunolabeling and confocal imaging. RGC function was evaluated using pattern electroretinography (PERG). Axonal sprouting was quantified by anterograde transport of cholera toxin B injected intravitreally. Myelin debris clearance was assessed in optic nerves in vivo and in vitro using bone-marrow-derived macrophages isolated from myeloid HDAC3 KO and control mice. Myeloid HDAC3 deletion preserved RGC and improved axonal regeneration after ONC, together with improved retinal function assessed by PERG. Furthermore, the deletion of HDAC3 enhanced the phagocytic function of myeloid cells to effectively remove apoptotic cells and myelin debris, both in vivo and in vitro. These protective effects were associated with the deletion of HDAC3 specifically in macrophages, since microglial-only deletion of HDAC3 did not preserve RGC count or function. The enhanced efferocytosis function of HDAC3 KO macrophages was at least partly dependent on increasing the expression of the phagocytic tyrosine kinase receptor, MerTK. The deletion of myeloid HDAC3 enhances efferocytosis, leading to neuroprotection, regeneration, and functional recovery following ONC. Targeting myeloid-HDAC3 presents a novel therapeutic strategy for TON.

## Linked entities

- **Genes:** HDAC3 (histone deacetylase 3) [NCBI Gene 8841], MERTK (MER proto-oncogene, tyrosine kinase) [NCBI Gene 10461]
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, ODC1 (ornithine decarboxylase 1) [NCBI Gene 4953] {aka BABS, NEDBA, NEDBIA, ODC}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, GAS6 (growth arrest specific 6) [NCBI Gene 2621] {aka AXLLG, AXSF}, Rbfox3 (RNA binding protein, fox-1 homolog (C. elegans) 3) [NCBI Gene 52897] {aka Fox-3, Hrnbp3, NeuN, Neuna60}, Hdac3 (histone deacetylase 3) [NCBI Gene 15183], Mbp (myelin basic protein) [NCBI Gene 17196] {aka Hmbpr, golli-mbp, jve, mld, shi}, Mertk (MER proto-oncogene tyrosine kinase) [NCBI Gene 17289] {aka Eyk, Mer, Nyk, nmf12}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, HDAC3 (histone deacetylase 3) [NCBI Gene 8841] {aka HD3, KDAC3, RPD3, RPD3-2}, Pou4f1 (POU domain, class 4, transcription factor 1) [NCBI Gene 18996] {aka Brn-3, Brn-3.0, Brn3, Brn3.0, Brn3a, E130119J07Rik}, Pcx (pyruvate carboxylase) [NCBI Gene 18563] {aka Pc, Pcb}, Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737], Rbpms (RNA binding protein gene with multiple splicing) [NCBI Gene 19663] {aka 2010300K22Rik, 2700019M19Rik, RBP-MS, hermes}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, TYRO3 (TYRO3 protein tyrosine kinase) [NCBI Gene 7301] {aka BYK, Dtk, Etk-2, RSE, Rek, Sky}, Odc1 (ornithine decarboxylase, structural 1) [NCBI Gene 18263] {aka ODC}, AXL (AXL receptor tyrosine kinase) [NCBI Gene 558] {aka ARK, AXL3, JTK11, Tyro7, UFO}, MERTK (MER proto-oncogene, tyrosine kinase) [NCBI Gene 10461] {aka MER, RP38, Tyro12, c-Eyk, c-mer}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}
- **Diseases:** neuronal cell loss (MESH:D002292), neuroinflammation (MESH:D000090862), central nervous system (CNS) injuries (MESH:D002493), inflammation (MESH:D007249), neurodegeneration (MESH:D019636), crush injury (MESH:D000071576), axonal degeneration (MESH:D009410), traumatic brain injury (MESH:D000070642), injury (MESH:D014947), ONC injury (MESH:D020221), blindness (MESH:D001766), dislocation (MESH:D004204), retinal neurodegeneration (MESH:D012164), RGC (MESH:D012173), IR (MESH:C537629), ONC (MESH:D000080344), ocular disorders (MESH:D005128), vision loss (MESH:D014786), neurological pathologies (MESH:D005598), RGC degeneration (MESH:D012162), retinitis pigmentosa (MESH:D012174)
- **Chemicals:** Tamoxifen (MESH:D013629), RGFP966 (MESH:C000603861), hematoxylin (MESH:D006416), DAPI (MESH:C007293), PFA (MESH:C003043), GlutaMAX (MESH:C054122), sucrose (MESH:D013395), AP (MESH:D000667), 4-OHT (MESH:C032278), glucose (MESH:D005947), N2 (MESH:D009584), lipids (MESH:D008055), UNC2025 (MESH:C000597431), proparacaine hydrochloride (MESH:C005717), Alexa Fluor  647 (MESH:C569686), BCA (MESH:C047117), 4-hydroxytamoxifen (MESH:C016601), ORO (MESH:C011049), xylazine (MESH:D014991), AF591 (-), phenylephrine (MESH:D010656), phosphate (MESH:D010710), isoflurane (MESH:D007530), streptomycin (MESH:D013307), tropicamide (MESH:D014331), Triton X-100 (MESH:D017830), Alexa 594 (MESH:C417664), penicillin (MESH:D010406)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), RPE — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0145), K-562 — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_0004)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13039952/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13039952/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC13039952/full.md

---
Source: https://tomesphere.com/paper/PMC13039952